logo

GRANULES vs LINCOLN: Stock Comparison

GRANULES INDIA vs LINCOLN PHARMAUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

GRANULES INDIA is the larger company by market capitalisation. GRANULES INDIA shows faster revenue growth, while LINCOLN PHARMA shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

GRANULES leads 2; LINCOLN leads 9 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

GRANULESLINCOLN

Valuation lens

What price are you paying?

Market CapContext only
₹22,358 Cr
₹1,023 Cr
P/E RatioLINCOLN has the lower reading
30.39x
10.61x ✓
P/B RatioLINCOLN has the lower reading
3.99x
1.35x ✓
EPSLINCOLN has the higher reading
₹7.26
₹18.09 ✓
Book ValueContext only
₹205.21
₹378.25
Dividend YieldLINCOLN has the higher reading
0.22%
0.35% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
GRANULES is the larger company
₹22,358 Cr vs ₹1,023 Cr
P/E Ratio
LINCOLN has a lower P/E
10.61x vs 30.39x
P/B Ratio
LINCOLN has a lower P/B
1.35x vs 3.99x
EPS
LINCOLN has higher earnings per share
₹18.09 vs ₹7.26
Dividend Yield
LINCOLN has a higher dividend yield
0.35% vs 0.22%
Revenue Growth (TTM YoY)
GRANULES has faster revenue growth
22.8% vs 11.4%
EPS Growth (TTM YoY)
GRANULES has faster EPS growth
31.3% vs 0.6%
ROE
LINCOLN has a higher ROE
11.6% vs 9.11%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricGRANULESLINCOLN
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricGRANULESLINCOLN
Live Price₹817₹510.85
Day Change1.16%-0.72%
Volume5.12 L61,149
52-Week High₹923.65₹770
52-Week Low₹529.85₹440
Distance from 52W High-11.55%-33.66%

Valuation

MetricGRANULESLINCOLN
Market Cap₹22,358 Cr₹1,023 Cr
P/E Ratio30.39x10.61x
P/B Ratio3.99x1.35x
EPS₹7.26₹18.09
Book Value₹205.21₹378.25
Dividend Yield0.22%0.35%

Growth

MetricGRANULESLINCOLN
Revenue Growth (TTM YoY)22.8%11.4%
EPS Growth (TTM YoY)31.3%0.6%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricGRANULESLINCOLN
ROE9.11%11.6%
ROCE9.07%10.97%
Net Margin11.15%13.1%
Operating Margin17.19%17.38%
Debt to Equity0.17x0.01x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricGRANULESLINCOLN
Promoter Holding37.08%▼ 0.59 pp49.78%
FII Holding20.25%▲ 2.75 pp4.6%▼ 0.59 pp
DII Holding15.33%▼ 0.78 pp0.27%▼ 0.82 pp
Public Holding27.04%▼ 1.34 pp45.36%▲ 1.42 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GRANULES INDIA and LINCOLN PHARMA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.